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Background
Vectored vaccines based on modified vaccinia Ankara
(MVA) may lead to new treatment options against infec-
tious diseases and certain cancers. MVA is highly atte-
nuated and requires avian cells for production. We
established avian continuous cell lines (including CR
and related CR.pIX) and adapted these cells to prolifera-
tion in single-cell suspension in a chemically defined
medium [1,2]. Replication of several viruses was efficient
in CR suspension cultures [3,4] but yields for MVA
were low. We suspected that cell-to-cell spread may be
an important mechanism for MVA replication in agi-
tated suspension cultures and developed a production
medium that is added at the time of infection to induce
cell aggregates [2]. MVA (and other host-restricted pox-
viruses) replicate to very high titers with this robust and
fully scalable cultivation protocol but further improve-
ment may facilitate production for large vaccine pro-
grams. We now describe a novel genotype of MVA that
replicates with high efficiency in single-cell suspensions
without aggregate induction.
Materials and methods
Motivated to discover new phenotypes, we quantified repli-
cation of successive MVA passages in aggregated CR sus-
pension cultures. Because titers increased slightly within 10
passages, viral genomic DNA of early and late passages was
sequenced. Of the advanced passage, a contiguous
sequence of 135 kb was recovered and revealed a genotype
(which we call MVA-CR) where the structural proteins
A3L, A9L and A34R (in vaccinia virus nomenclature) each
carry a single amino acid exchange (Figure 1A). The novel
genotype appears to accumulate in our system but to com-
pletely remove traces of wildtype plaque purification was
performed. The pure isolate (called MVA-CR19) was
further characterized and compared to the wildtype.
Results
The aggregate-based process was developed to facilitate
cell-to-cell spread, which appears to be an important
mechanism for vaccinia virus replication. Surprisingly,
multiplication of MVA-CR19 appears to be efficient also
in single-cell avian suspension cultures (Figure 1B) with
increased infectious titers in the cell-free supernatant.
Because of this qualitative difference between wildtype and
MVA-CR19, we hypothesized that a smaller fraction of the
MVA-CR isolate remains cell associated and that this
capacity allows viruses of the novel genotype to spread
also in single cell suspensions. As one test of our proposed
explanation we repeated the passaging experiments in
adherent cultures. No mutations in the three genes that
distinguish MVA-CR were detected, suggesting that the
contribution of host cell properties to the observed
changes in the virus population recovered from the sus-
pension process may be negligible.
However, the MVA-CR phenotype is evident also in
adherent cells: compared to wildtype MVA, plaques
formed by MVA-CR19 on CR cell monolayers in comet
assays appear to be larger and to develop earlier [5]. These
results are consistent with mechanisms that allow MVA-
CR19 to replicate, infect or uncoat faster, or be released
with greater efficiency from host cells. For further charac-
terization of this effect, adherent cells were infected with a
high multiplicity of 10 and briefly subjected to a pH shift.
This is predicted to activate the viral fusion apparatus so
that cell-associated viruses in a confluent cell monolayer
can induce formation of syncitia [6]. As shown in Figure
1C, cell fusion appears to be less pronounced in cultures
infected with MVA-CR suggesting that either fewer virions
of this genotype remain cell associated or that fusion may
be less important for entry of such virions.* Correspondence: ingo.jordan@probiogen.de
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A molecular basis for the proposed improved MVA-
CR19 dissemination is that all three of the observed
mutations each target a different component of the com-
plex viral particles, the core and the different membranes
of the mature intracellular and extracellular virions. We
are in the process of generating various combinations of
recombinant MVAs to determine whether all three fac-
tors need to cooperate to produce the observed effects or
whether a single gain of function mutation in any one or
two factors is sufficient.
Conclusions
Compared to wildtype MVA, plaques formed by MVA-
CR19 on adherent CR cells appear to be larger and to
develop earlier. Titers are slightly higher in complete
lysates and significantly elevated in cell-free supernatants.
MVA-CR19 replicates efficiently without aggregate induc-
tion also in single cell suspension cultures. We hypothe-
size that a greater fraction of MVA-CR19 escapes the
hosts for infection of distant targets. In such a model the
new genotype should not confer a significant advantage to
Figure 1 (A) Schematic of the genomic DNA of MVA-CR. The region covered by next generation sequencing is shown together with the
mutations (in single letter code for amino acids, e.g. H639Y is His639 ® Tyr) in the three genes. ITR (viral telomers) and deletion sites in MVA as
light gray boxes are shown for orientation. (B) CR.pIX single-cell suspension cultures were infected with wildtype (wt) and MVA-CR19. Cells were
immunostained for virus antigens 48 h post infection and quantified by FACS to investigate differences in the dissemination of infectious units
in absence of aggregate induction. (C) Cell fusion is induced by wildtpe MVA but less so by MVA-CR19. Red immunofluorescence against MVA
antigens serves as a positive control for infection. Blue fluorescence of DNA is shown for orientation. MVA-negative cells next to infected cells
are shown in the panels where virus was added to a multiplicity of infection (MOI) of 0.1.
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viruses spreading in cell monolayers, and indeed we could
not generate the MVA-CR genotype by passaging in
adherent cultures. Attenuation has yet to be confirmed for
MVA-CR but host cell-restriction appears to have been
fully maintained for Vero and HEK 293 cells.
Supply of an injectable vaccine preparation may be
facilitated with this strain as production in single cell sus-
pension using only a cell proliferation medium is less com-
plex compared to the current protocol that requires cell
aggregate induction by addition of a virus production
medium. Furthermore, MVA-CR has a tendency to accu-
mulate in the extracellular volume. Purification of live
virus out of a cell-free suspension may allow enhanced
purity compared to a process that initiates with a complete
lysate containing the full burden of unwanted host cell-
derived components.
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